The nature of activatory and tolerogenic dendritic cell-derived signal II
- PMID: 23450201
- PMCID: PMC3584294
- DOI: 10.3389/fimmu.2013.00053
The nature of activatory and tolerogenic dendritic cell-derived signal II
Abstract
Dendritic cells (DCs) are central in maintaining the intricate balance between immunity and tolerance by orchestrating adaptive immune responses. Being the most potent antigen presenting cells, DCs are capable of educating naïve T cells into a wide variety of effector cells ranging from immunogenic CD4(+) T helper cells and cytotoxic CD8(+) T cells to tolerogenic regulatory T cells. This education is based on three fundamental signals. Signal I, which is mediated by antigen/major histocompatibility complexes binding to antigen-specific T cell receptors, guarantees antigen specificity. The co-stimulatory signal II, mediated by B7 family molecules, is crucial for the expansion of the antigen-specific T cells. The final step is T cell polarization by signal III, which is conveyed by DC-derived cytokines and determines the effector functions of the emerging T cell. Although co-stimulation is widely recognized to result from the engagement of T cell-derived CD28 with DC-expressed B7 molecules (CD80/CD86), other co-stimulatory pathways have been identified. These pathways can be divided into two groups based on their impact on primed T cells. Whereas pathways delivering activatory signals to T cells are termed co-stimulatory pathways, pathways delivering tolerogenic signals to T cells are termed co-inhibitory pathways. In this review, we discuss how the nature of DC-derived signal II determines the quality of ensuing T cell responses and eventually promoting either immunity or tolerance. A thorough understanding of this process is instrumental in determining the underlying mechanism of disorders demonstrating distorted immunity/tolerance balance, and would help innovating new therapeutic approaches for such disorders.
Keywords: T cell priming; activation; co-inhibition; co-stimulation; dendritic cells; tolerance.
Figures
References
-
- Agata Y., Kawasaki A., Nishimura H., Ishida Y., Tsubata T., Yagita H., et al. (1996). Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8 765–772 - PubMed
-
- Akiba H., Nakano H., Nishinaka S., Shindo M., Kobata T., Atsuta M., et al. (1998). CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase. J. Biol. Chem. 273 13353–13358 - PubMed
-
- Alegre M. L., Noel P. J., Eisfelder B. J., Chuang E., Clark M. R., Reiner S. L., et al. (1996). Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J. Immunol. 157 4762–4770 - PubMed
-
- Anderson A. C., Anderson D. E., Bregoli L., Hastings W. D., Kassam N., Lei C., et al. (2007). Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 318 1141–1143 - PubMed
-
- Ara G., Baher A., Storm N., Horan T., Baikalov C., Brisan E., et al. (2003). Potent activity of soluble B7RP-1-Fc in therapy of murine tumors in syngeneic hosts. Int. J. Cancer 103 501–507 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
